|
Pharmaceutical and biotechnology companies are under increasing pressure to improve the speed of drug development. The figures are well known; the average cost to develop a drug to the post approval stage is reported by the Tufts Centre to be $890 million.
The introduction of technology has been one way in which companies have tried to improve their clinical trial processes. However, the move to replace paper with eClinical technologies has brought new challenges, the challenges that you face every day.
Assero are committed to helping pharmaceutical companies in the adoption of data interchange standards, focusing on the Clincial Data Interchange Standards Consortium (CDISC) Operational Data Model (ODM). Assero develop tools to assist companies comply with the standard and also help deploy the model in conjunction with the other CDISC models as part of the true eClinical trial. The company is a member of CDISC and actively supports the standards body in its activities, both in Europe and globally.
Use the menu to the left to find out more....
Assero Limited
A CDISC Registered Solutions Provider
|
|
Recent Events:
Current e-Source Acceptance
DIA Euro Meeting 2008. Barcelona. March 3-5, 2008.
The Ever Expanding Role of the ODM
DIA 16th Annual CDM Conference.. Basel, Switzerland. November 5-8, 2006.
Published Articles:
The CDISC Operational Data Model: Ready To Roll?
Applied Clinical Trials. July 2004. Read it here.
|
|
